|
|
The Liver Meeting |
|
|
|
|
October 29 - November 2 |
Welcome to the HBV Advocate’s AASLD Conference coverage. In an effort to best serve our readership, we will post all the important and interesting abstracts about HBV from the conference. While attending the conference, we will update any abstracts that we personally cover at the conference. The updated abstracts will be marked with the date that they have been updated and posted. The other abstracts posted to the web site are HBV related abstracts posted to www.aasld.org that we have not been able to report on or update.
To locate specific abstracts on this page, click on “Edit” at the top of your browser (Microsoft Internet Explorer) and then on Find (on this page). In Netscape, click on “Search” and then on “Find in This Page.” Simply type in a word or term and the search engine will list the related abstracts.
Please click here to view our fact sheet on reading and understanding an abstract.
Thank You,
Alan
Franciscus
Editor-in-Chief
Hepatitis
B
HBV Antiviral
Treatment
Lamivudine
§
EFFECT OF LAMIVUDINE THERAPY ON THE SERUM
COVALENTLY CLOSED CIRCULAR DNA OF CHRONIC HEPATITIS B INFECTION (updated 11/03/2004)
§
LAMIVUDINE TREATMENT FOR ACUTE SEVERE
HEPATITIS B (updated 11/03/2004)
§
THE LONG-TERM OUTCOME OF HBeAG-NEGATIVE PATIENTS WITH CIRRHOSIS TREATED WITH
LAMIVUDINE MONOTHERAPY: A 5-YEAR PROSPECTIVE COHORT STUDY (updated 11/03/2004)
§
DYNAMICS OF HBV-DNA AND INFECTED
HEPATOCYTES DESCRIBED BY A NEW BIO-MATHEMATICAL MODEL IN CHRONIC HEPATITIS B
PATIENTS TREATED WITH LAMIVUDINE AND IN PATIENTS WITH YMDD MUTANTS TREATED WITH
ADEFOVIR (updated 11/03/2004)
Adefovir
§
ONE YEAR RESULTS FROM A MULTI-CENTRE,
DOUBLE-BLIND, PLACEBO (PLA)-CONTROLLED 5 YEAR STUDY OF ADEFOVIR DIPIVOXIL (ADV)
IN CHINESE PATIENTS WITH HBEAG POSITIVE CHRONIC HEPATITIS B (CHB) (updated 11/01/2004)
§
DIFFERENT
PROFILES OF RESPONSE TO ADEFOVIR DIPIVOXIL AND FACTORS THAT MAY INFLUENCE RESPONSE
IN PATIENTS WITH CHRONIC HEPATITIS B (updated 11/03/2004)
§
ANALYSIS
OF HBV POLYMERASE POLYMORPHISMS AND VIROLOGICAL RESPONSE TO ADEFOVIR DIPIVOXIL
(ADV) IN CHRONIC HEPATITIS B (CHB) PATIENTS (updated 11/03/2004)
§
LONG
TERM EFFICACY AND SAFETY OF ADEFOVIR DIPIVOXIL (ADV) 10 MG IN HBEAG+ CHRONIC
HEPATITIS B (CHB) PATIENTS: INCREASING SEROLOGIC, VIROLOGIC AND BIOCHEMICAL
RESPONSE OVER TIME (updated 11/03/2004)
§
RANDOMIZED,
DOUBLE-BLIND STUDY COMPARING ADEFOVIR DIPIVOXIL (ADV) PLUS EMTRICITABINE (FTC)
COMBINATION THERAPY VERSUS ADV ALONE IN HBEAG (+) CHRONIC HEPATITIS B: EFFICACY
AND MECHANISMS OF TREATMENT RESPONSE (updated 11/03/2004)
§
CONTINUED
EFFICACY AND SAFETY OF ADEFOVIR DIPIVOXIL IN CHRONIC HEPATITIS B PATIENTS WITH
LAMIVUDINE RESISTANT HBV: 1 YEAR RESULTS (updated 11/03/2004)
Emtricitabine, FTC
§
A DOUBLE-BLIND,
PLACEBO-CONTROLLED TRIAL OF EMTRICITABINE (FTC, EMTRIVA) ADMINISTERED
ONCE-DAILY FOR TREATMENT OF CHRONIC HEPATITIS B VIRUS (HBV) INFECTION (updated 10/31/2004)
§
CORRELATION
BETWEEN BASELINE GENOTYPE AND ANTIVIRAL RESPONSE TO EMTRICITABINE 200 MG QD
AMONG HBEAG NEGATIVE PATIENTS WITH CHRONIC HEPATITIS B INFECTION (updated 11/03/2004)
Entecavir
§
ENTECAVIR DEMONSTRATES SUPERIOR
HISTOLOGIC AND VIROLOGIC EFFICACY OVER LAMIVUDINE IN NUCLEOSIDE-NAIVE HBEAG(-)
CHRONIC HEPATITIS B: RESULTS OF PHASE III TRIAL ETV-027 (updated 11/01/2004)
§
ENTECAVIR IS SUPERIOR TO
LAMIVUDINE FOR THE TREATMENT OF HBEAG(+) CHRONIC HEPATITIS B: RESULTS OF PHASE
III STUDY ETV-022 IN NUCLEOSIDE-NAďVE PATIENTS
(updated
10/31/2004)
§
ENTECAVIR IS SUPERIOR TO LAMIVUDINE AT REDUCING
HBV DNA IN PATIENTS WITH CHRONIC HEPATITIS B REGARDLESS OF BASELINE ALANINE
AMINOTRANSFERASE LEVELS (updated 11/03/2004)
§
EMERGENCE OF ENTECAVIR RESISTANT
HEPATITIS B VIRUS AFTER ONE YEAR OF THERAPY IN PHASE II & III STUDIES IS
ONLY OBSERVED IN LAMIVUDINE REFRACTORY PATIENTS (updated 11/03/2004)
§
HEPATIC
IMPAIRMENT DOES NOT ALTER SINGLE-DOSE PHARMACOKINETICS AND SAFETY OF ENTECAVIR
(updated 11/03/2004)
§
ENTECAVIR
IS SUPERIOR TO CONTINUED LAMIVUDINE FOR THE TREATMENT OF LAMIVUDINE-REFRACTORY,
HBeAG(+) CHRONIC HEPATITIS B: RESULTS OF PHASE III
STUDY ETV-026 (updated
11/03/2004)
§
ENTECAVIR
IS WELL-TOLERATED FOR TREATMENT OF CHRONIC HEPATITIS B: PHASE III SAFETY
ANALYSIS IN NUCLEOSIDE-NAďVE AND
LAMIVUDINE-REFRACTORY PATIENTS (updated 11/03/2004)
§
A
RANDOMIZED, PLACEBO-CONTROLLED STUDY (ETV-056) IN CHINA OF THE EFFICACY AND
SAFETY OF ENTECAVIR IN CHRONIC HEPATITIS B PATIENTS WHO HAVE FAILED LAMIVUDINE
(updated 11/03/2004)
Clevudine
§
A PHASE II, RANDOMIZED TRIAL EVALUATING THE
SAFETY, PHARMACOKINETICS AND ANTIVIRAL ACTIVITY OF CLEVUDINE FOR 12 WEEKS IN
PATIENTS WITH CHRONIC HEPATITIS B (updated 11/03/2004)
§
A
12-WEEK CLEVUDINE THERAPY SHOWED DURABLE ANTIVIRAL ACTIVITY AND NORMALIZATION
OF ALANINE TRANSMINASE LEVELS FOR 6 MONTHS AFTER DISCONTINUATION OF TREATMENT
IN PATIENTS WITH CHRONIC HEPATITIS B (updated 11/03/2004)
§
CLEVUDINE
RE-ADMINISTERED TO THE PATIENTS WITH PREVIOUS 12-WEEKS CLEVUDINE EXPERIENCE IS
AS ACTIVE AS TO THE NAIVE PATIENTS IN TERMS OF VIROLOGICAL AND BIOCHEMICAL
RESPONSES (updated
11/03/2004)
Tenofovir
§
EFFECT OF SWITCHING TO TENOFOVIR WITH
EMTRICITABINE OR LAMIVUDINE IN PATIENTS WITH CHRONIC HEPATITIS B FAILING TO
RESPOND TO AN ADEFOVIR-CONTAINING REGIMEN (updated
11/03/2004)
Telbivudine
§
CLINICAL PHARMACOKINETICS OF TELBIVUDINE,
A POTENT ANTIVIRAL FOR HEPATITIS B, IN SUBJECTS WITH IMPAIRED HEPATIC OR RENAL
FUNCTION (updated 11/03/2004)
Other Antivirals
§
PHASE I/II DOUBLE-BLIND, RANDOMIZED,
PLACEBO-CONTROLLED STUDY OF THE NOVEL ANTI-HBV AGENT LB80380/ANA380 IN PATIENTS
WITH CHRONIC HBV INFECTION (updated
11/01/2004)
§
VALTORCITABINE PROVIDES POTENT
SUPPRESSION OF HEPATITIS B VIRUS IN PATIENTS WITH CHRONIC HEPATITIS B: RESULTS
OF A PHASE I/II CLINICAL TRIAL (updated 11/01/2004)
§
CORRELATES OF RESPONSE IN PATIENTS WITH
CHRONIC HBV INFECTION RECEIVING LIBIVIRUMAB AND EXBIVIRUMAB (HEPEX-B(tm)) (updated 11/03/2004)
§
IN VITRO CHARACTERISATION OF THE ANTI-HBV
ACTIVITY AND CROSS-RESISTANCE PROFILE OF 2',3'-DIDEOXY-3'-FLUOROGUANOSINE (updated 11/03/2004)
§
BINDING AND INHIBITION OF HEPATITIS B
VIRUS C GENE PROMOTER BY ADENO-ASSOCIATED VIRUS REP78 PROTEIN IN VITRO (updated 11/03/2004)
§
SAFETY, TOLERANCE, PHARMACOKINETICS AND
PHARMACODYNAMICS OF REMOFOVIR, A LIVER-TARGETING PRODRUG OF PMEA IN HBV
PATIENTS FOLLOWING DAILY DOSING FOR 28 DAYS (updated
11/03/2004)
THERAPEUTIC VACCINES
§
INDUCTION OF HBS-SPECIFIC T CELL RESPONSES
IN HBV CHRONIC CARRIERS BY AN HEPATITIS B VIRUS DNA VACCINE (updated 11/01/2004)
§
PRODUCTION OF IMMUNOGENIC
HBSAG-PULSED HUMAN DENDRITIC CELLS (DCS): EVALUATION OF SAFETY AND EFFICACY OF
HBSAG-PULSED DCS IN NORMAL VOLUNTEERS, HB VACCINE NONRESPONDERS AND PATIENTS
WITH CHRONIC HEPATITIS B (updated 11/01/2004)
§
VACCINATION WITH AN EXPERIMENTAL
ANTI-HBV VACCINE YIELDS HIGH RESPONSE RATES IN LIVER TRANSPLANT PATIENTS AND
ALLOWS SAFE DISCONTINUATION OF HEPATITIS B IMMUNOGLOBULINS PROPHYLAXIS
(updated
11/01/2004)
§
DEVELOPMENT
OF A NON-REPLICATIVE, SINGLE-SHOT DNA-BASED VACCINE EXPRESSING ALL HEPATITIS B
VIRAL ANTIGENS (updated
11/03/2004)
§
BREAKING
IMMUNE TOLERANCE IN CHRONIC HEPATITIS B BY DENDRITIC CELL VACCINATION IN HBV
TRIMERA MICE (updated
11/03/2004)
§
SAFETY,
IMMUNOGENICITY, AND EFFICACY RESULTS OF A PHASE II TRIAL OF THERAPEUTIC
VACCINES FOR CHRONIC HBV IN THE GAMBIA (updated 11/03/2004)
HBV INTERFERON
TREATMENT
§
SUCCESSFUL TREATMENT WITH PEGYLATED
INTERFERON IN HBV NON-RESPONDERS TO STANDARD INTERFERON AND LAMIVUDINE (updated 11/03/2004)
§
BETTER
SAFETY AND QUALITY OF LIFE IN PATIENTS WITH CHRONIC HEPATITIS B THAN IN
PATIENTS WITH CHRONIC HEPATITIS C WHEN TREATED WITH PEGINTERFERON ALFA-2A
(40KD) (PEGASYS(r)) MONOTHERAPY (updated 11/03/2004)
Combination Antiviral and Interferon Treatment
§
RANDOMIZED, DOUBLE-BLIND STUDY COMPARING ADEFOVIR
DIPIVOXIL (ADV) PLUS EMTRICITABINE (FTC) COMBINATION THERAPY VERSUS ADV ALONE
IN HBeAG (+) CHRONIC HEPATITIS B: EFFICACY AND
MECHANISMS OF TREATMENT RESPONSE (updated 11/03/2004)
§
HBSAG
SEROCONVERSION IN CHRONIC HBV PATIENTS TREATED WITH PEGYLATED INTERFERON
ALPHA-2B ALONE OR IN COMBINATION WITH LAMIVUDINE. THE ROLE OF HBV GENOTYPE (updated 11/03/2004)
§
HBV
VIRAL DYNAMICS DURING TREATMENT OF NAIVE PATIENTS WITH HBEAG(-) CHRONIC
HEPATITIS B WITH PEGYLATED INTERFERON ALPHA 2B ALONE OR IN COMBINATION WITH
LAMIVUDINE (updated
11/03/2004)
HBV VIRAL RESISTANCE TO DRUGS
§
CHANGES IN THE STABILITY OF HBV-SPECIFIC
CTL EPITOPES BY YMDD MUTATIONS MAY DETERMINE THE OCURRENCE OF BREAKTHROUGH
HEPATITIS (updated 11/01/2004)
§
HBV MUTANTS ASSOCIATED WITH
CLINICAL RESISTANCE TO ADEFOVIR DIPIVOXIL DISPLAY ONLY SMALL DECREASES IN
ANTIVIRAL SENSITIVITY IN VITRO (updated 11/01/2004)
§
HEPATITIS B VIRUS RESISTANCE TO
ENTECAVIR INVOLVES NOVEL CHANGES IN THE VIRAL POLYMERASE (updated 11/01/2004)
§
IN VITRO CROSS-RESISTANCE
TESTING OF ADEFOVIR, LAMIVUDINE, TELBIVUDINE (L-DT), ENTECAVIR AND OTHER
ANTI-HBV COMPOUNDS AGAINST FOUR MAJOR MUTATIONAL PATTERNS OF
LAMIVUDINE-RESISTANT HBV (updated 11/01/2004)
§
LOW LIVER CELL PROLIFERATION
AND HIGH APOPTOSIS RATES IN PATIENTS WITH HBeAG-NEGATIVE
CHRONIC HEPATITIS B RESPONDING TO INTERFERON (updated 11/01/2004)
§
MOLECULAR MODELLING OF
ENTECAVIR RESISTANT MUTATIONS IN THE HEPATITIS B VIRUS POLYMERASE SELECTED
DURING THERAPY (updated 11/01/2004)
§
MOLECULAR MODELLING OF
HEPATITIS B VIRUS POLYMERASE AND ADEFOVIR RESISTANCE IDENTIFIES THREE CLUSTERS
OF MUTATIONS (updated 11/01/2004)
§
VIRAL DYNAMICS FOR LDT
(TELBIVUDINE)-TREATED HEPATITIS B PATIENTS: HIGH DEGREE OF INITIAL INHIBITION
WITH DOSE-DEPENDENT SECOND-PHASE HBV CLEARANCE SUGGESTS A NEW MODEL FOR HBV
DYNAMICS (updated 11/01/2004)
§
PREDICTION OF BREAKTHROUGH HEPATITIS DUE
TO LAMIVUDINE-RESISTANT HEPATITIS B VIRUS BY A SENSITIVE S EMI-QUANTITATIVE
ASSAY FOR THE MUTANT VIRUS (updated 11/03/2004)
§
DETECTION
OF PREDOMINANT YMDD MUTANTS AT THE STAGE OF VIRAL DNA NEGATIVITY FOR THE
PROGNOSIS OF VIRAL DNA BREAKTHROUGH (updated 11/03/2004)
§
EARLY
VIRAL KINETICS DURING THERAPY WITH LAMIVUDINE PLUS ADEFOVIR DIPIVOXIL IN
PATIENTS WITH LAMIVUDINE RESISTANT CHRONIC HEPATITIS B (updated 11/03/2004)
§
A NOVEL
LINE PROBE ASSAY (INNO-LIPA HBV DR V2) FOR DETECTING DRUG RESISTANCE IN
HEPATITIS B VIRUS INFECTED PATIENTS DURING LAMIVUDINE AND ADEFOVIR DIPIVOXIL
THERAPY (updated
11/03/2004)
HBV PREVENTION
§
EFFICACY AND SAFETY OF LAMIVUDINE IN LATE
PREGNANCY FOR THE PREVENTION OF MOTHER-CHILD TRANSMISSION OF HEPATITIS B; A
MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (updated 11/03/2004)
HBV and Liver Transplants
§
HBSAG LEVEL AT TIME OF LIVER
TRANSPLANTATION PREDEFINES EARLY HBSAG AND ANTI-HBS KINETICS AND AFFECTS
HBV-DNA DECREASE DURING IMMUNOGLOBULIN ADMINISTRATION (updated 11/01/2004)
§
LAMIVUDINE MONO PROPHYLAXIS FOR
LIVER TRANSPLANT RECIPIENTS WITH HEPATITIS B-SINGLE CENTER EXPERIENCE OVER 10
YEARS (updated
11/01/2004)
§
LAMIVUDINE PROPHYLAXIS WITH
ADEFOVIR SALVAGE IN HEPATITIS B PATIENTS UNDERGOING LIVER TRANSPLANT IS MORE
COST EFFECTIVE THAN COMBINATION LAMIVUDINE/HBIG THERAPY (updated 11/01/2004)
§
LIVER TRANSPLANTATION FOR
HEPATITIS B ASSOCIATED END STAGE LIVER DISEASE IN KOREA (updated 11/01/2004)
§
LIVER TRANSPLANTATION IN
LAMIVUDINE-RESISTANT YMDD-MUTANT CARRIERS: ROLE OF ADEFOVIR-DIPIVOXIL IN
PREVENTION OF HEPATITIS B VIRUS RECURRENCE (updated 11/01/2004)
§
LIVING DONOR LIVER
TRANSPLANTATION FROM HEPATITIS B CORE ANTIBODY POSITIVE DONORS (updated 11/01/2004)
§
RELATION BETWEEN HBV GENOTYPES
AND HBV VARIANTS AND INDICATIONS FOR LIVER TRANSPLANT (LT) IN HEPATITIS B
PATIENTS IN THE U.S.* (updated 11/01/2004)
§
THE EFFECT OF HEPATITIS B
REPLICATION STATUS ON HEPATITIS B IMMUNOGLOBULIN DOSE REQUIREMENTS AND
PHARMACOKINETICS IN LIVER TRANSPLANTATION FOR HEPATITIS B VIRUS (updated 11/01/2004)
§
TREATMENT OF LAMIVUDINE
RESISTANCE HEPATITIS B PATIENTS AFTER LIVER TRANSPLANT: RESULTS OF A SINGLE
CENTER EXPERIENCE (updated 11/01/2004)
HBV AND LIVER CANCER
§
CHANGE OF HEPATITIS B VIRUS
ACTIVITIES WITH TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION THERAPY IN PATIENTS
WITH HBV-RELATED HEPATOCELLULAR CARCINOMA (updated 11/01/2004)
§
HEPATITIS B VIRAL LOAD IS
ASSOCIATED WITH THE DEVELOPMENT OF HEPATOCELLULAR CARCINOMA (HCC) (updated 11/01/2004)
§
HEPATITIS B VIRUS-RELATED
INSERTIONAL MUTAGENESIS IN PATIENTS WITH CHRONIC HEPATITIS B AS AN EARLY DRASTIC
GENETIC CHANGE LEADING TO HEPATOCARCINOGENESIS (updated 11/01/2004)
§
IMPROVED SURVIVAL WITH
SCREENING FOR HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B - PRELIMINARY
RESULTS OF A NATIONAL SURVEILLANCE PROGRAM (updated 11/01/2004)
HBV PREVALENCE AND PUBLIC POLICY
§
OCCULT HEPATITIS B VIRUS INFECTION IN A
NORTH AMERICAN ADULT HEMODIALYSIS PATIENT POPULATION (updated 11/01/2004)
§
OCCULT HEPATITIS B VIRUS
INFECTION IN A COMMUNITY-BASED POPULATION (updated 11/01/2004)
§
HIGH PREVALENCE OF CHRONIC HEPATITIS B (HBV)
INFECTION IN ADULT CHINESE AMERICANS LIVING IN CALIFORNIA (updated 11/03/2004)
§
INPATIENT COSTS OF LIVER CIRRHOSIS AND
HEPATOCELLULAR CARCINOMA IN THE UNITED STATES, 1993-2001 (updated 11/03/2004)
HBV GENOTYPES
§
A CASE-CONTROL STUDY FOR DIFFERENCES
AMONG HEPATITIS B VIRUS INFECTIONS OF GENOTYPES A (SUBTYPES AA AND AE) AND D
(updated 11/01/2004)
§
MBL2 GENOTYPES ARE IMPORTANT
DETERMINANTS OF HBV CLEARANCE OR PERSISTENCE (updated 11/01/2004)
§
SUBTYPES OF HBV GENOTYPE A IN
THE UNITED STATES - CLINICAL SIGNIFICANCE AND IDENTIFICATION OF A NOVEL SUBTYPE
(updated
11/01/2004)
§
HBSAG
SEROCONVERSION IN CHRONIC HBV PATIENTS TREATED WITH PEGYLATED INTERFERON
ALPHA-2B ALONE OR IN COMBINATION WITH LAMIVUDINE. THE ROLE OF HBV GENOTYPE (updated 11/03/2004)
§
CLINICAL
SIGNIFICANCE OF HEPATITIS B VIRUS DNA LEVELS IN HBEAG-NEGATIVE, HBV GENOTYPE
D-INFECTED PATIENTS (updated 11/03/2004)
HBeAg-Negative Hepatitis B
§
NATURALLY OCCURRING MUTATIONS IN
HEPATITIS B VIRUS CORE GENE MODULATE CORE PROTEIN AND e ANTIGEN EXPRESSION OR
THEIR ANTIGENICITY(updated 11/01/2004)
§
PREDICTION OF LONG-TERM
PROGNOSIS OF HEPATITIS B VIRUS CARRIERS WITH NEGATIVE HBe
ANTIGEN AND NORMAL TRANSAMINASE LEVEL(updated 11/01/2004)
§
SERUM HBV-DNA LEVELS HIGHER
THAN 105 CP/ML ARE ASSOCIATED WITH SIGNIFICANT INFLAMMATORY ACTIVITY IN THE
LIVER OF HBeAG NEGATIVE HBSAG CARRIERS WITH
PERSISTENTLY NORMAL OR ELEVATED ALT (updated 11/01/2004)
§
THE PREVALENCE OF HBV
GENOTYPES, VIRAL VARIANTS AND HBeAG-VE CHRONIC
HEPATITIS B (E-CHB) IN A CANADIAN CENTER (updated 11/01/2004)
§
ACCUMULATION
OF BASIC CORE PROMOTER MUTATIONS DURING THE NATURAL COURSE OF HBV INFECTION
(updated 11/03/2004)
§
LONG-TERM
OUTCOME OF PATIENTS WITH HBeAG-NEGATIVE CHRONIC
HEPATITIS B (CHBe-) UNDER NUCLEOS(T)IDE ANALOGUES
MAINTENANCE THERAPY STARTING WITH LAMIVUDINE (LAM) (updated 11/03/2004)
HBV Disease Progression
§
BMI IS AN INDEPENDENT PREDICTOR OF
DISEASE PROGRESSION IN PATIENTS WITH CHRONIC HEPATITIS B (updated 11/01/2004)
§
VIRAL
LOAD AS A PREDICTOR OF LIVER DISEASE IN CHRONIC HEPATITIS B INFECTION (updated 11/01/2004)
§
DYNAMIC
RANGE AND REPRODUCIBILITY OF COBAS TAQMAN DETECTION OF HEPATITIS B VIRUS DNA
(updated 11/03/2004)
§
HEPATITIS
B VIRUS LAMIVUDINE RESISTANT MUTATIONS ABROGATE SECRETION OF HEPATITIS DELTA
VIRUS (updated
11/03/2004)
§ INVOLVEMENT OF HEPATITIS B VIRUS (HBV) COVALENTLY CLOSED CIRCULAR DNA IN SUSTAINED HBV REPLICATION IN IMMUNOCOMPROMISED MICE AFTER HYDRODYNAMIC INJECTION OF A NAKED PLASMID ENCODING HBV DNA (updated 11/03/2004)
§
QUANTITATIVE DETECTION OF (-) AND (+)
STRAND HBV DNA AND THEIR REPLICATIVE INTERMEDIATES IN THE LIVER OF CHRONICALLY
INFECTED PATIENTS (updated 11/03/2004)
HBV, HCV AND HIV
COINFECTIONS
§
IMPACT
OF HAART ON HEPATITIS B VIRUS CO-INFECTION: ASSOCIATION BETWEEN IMMUNORESTORATION
AND HBS/E ANTIGEN SEROCONVERSION (updated 11/03/2004)
§
LONGITUDINAL
EVALUATION OF VIROLOGICAL PROFILES IN HBV/HCV COINFECETED PATIENTS, AN ITALIAN
MULTICENTRE STUDY (updated 11/03/2004)
§
HEPATITIS
B VIRUS (HBV) RESPONSE TO THERAPY WITH LAMIVUDINE (LAM) AND TENOFOVIR (TFV) IN
HBV/HIV CO-INFECTED PATIENTS: IMPACT OF GENOTYPE AND TREATMENT REGIMEN (updated 11/03/2004)
§
CHARACTERISTICS
OF HEPATITIS B VIRUS (HBV) AND HIV CO-INFECTED PATIENTS IN FRANCE: A
PROSPECTIVE MULTICENTER SURVEY (updated 11/03/2004)
§
LONG
TERM EFFECTS OF INTERFERON ALPHA THERAPY INTRAVENOUS DRUG USERS WITH TRIPLE
INFECTION BY HEPATITIS B, C AND D VIRUS (updated 11/03/2004)
HBV AND THE IMMUNE SYSTEM
§
A SHORT SEQUENCE IN THE 3' END OF CORE
GENE IS CRITICAL FOR HEPATITIS B VIRUS GENOME REPLICATION, E ANTIGEN
PROCESSING, AND CORE PROTEIN NUCLEAR LOCALIZATION (updated 11/01/2004)
§
ANALYSIS OF INTRAHEPATIC IMMUNE
RESPONSE IDENTIFIES FOUR STAGES OF CHRONIC HBV INFECTION (updated 11/01/2004)
§
CHRONIC HBV PATIENTS DISPLAY
IMPAIRED MATURATION AND ANTIGEN PRESENTATION OF MYELOID DENDRITIC CELLS AND
REDUCED IFN-a PRODUCTION OF PLASMACYTOID DENDRITIC CELLS (updated 11/01/2004)
§
CYTOPATHIC EFFECTS OF HEPATITIS
B VIRUS INFECTION IN LONG-TERM INFECTED CHIMERIC UPA-SCID MICE (updated 11/01/2004)
§
EDITING OF HEPATITIS B VIRUS DNA BY THE
CYTIDINE DEAMINASE APOBEC3G (updated 11/01/2004)
§
FUNCTIONAL VARIATION IN THE IFNAR2
AND IL10RB GENES LINKED TO PERSISTENT HBV INFECTION (updated 11/01/2004)
§
HBX AND THE CELLULAR
ACETYLTRANSFERASE PCAF ARE CO-RECRUITED IN VIVO ONTO THE HBV CCCDNA
MINICHROMOSOME TO REGULATE THE COUPLED VIRAL TRANSCRIPTION/REPLICATION PROCESS
(updated
11/01/2004)
§
IMPAIRED CAPACITY OF LIVER
DENDRITIC CELLS FROM MURINE HEPATITIS B VIRUS (HBV) CARRIER TO INDUCE AND
SUSTAIN HBV-SPECIFIC ANTIVIRAL IMMUNITY: RELEVANCE TO HBV PERSISTENCY (updated 11/01/2004)
§
IMPAIRED TOLL-LIKE RECEPTOR
EXPRESSION IN CHRONIC HEPATITIS B: IMPLICATIONS FOR PATHOGENESIS AND THERAPY
(updated
11/01/2004)
§
INTERACTION OF HBV VARIANTS
DETERMINES THE PHENOTYPE OF A HETEROGENEOUS VIRAL POPULATION (updated 11/01/2004)
§
LOW LIVER CELL PROLIFERATION
AND HIGH APOPTOSIS RATES IN PATIENTS WITH HBeAG-NEGATIVE
CHRONIC HEPATITIS B RESPONDING TO INTERFERON (updated 11/01/2004)
§
MECHANISMS OF
HYPORESPONSIVENESS OF HBV-SPECIFIC CD4+ T CELLS IN CHRONIC HEPATITIS B (updated 11/01/2004)
§
REGULATORY T CELLS CONTRIBUTE
TO IMMUNOLOGIC HYPORESPONSIVENESS IN CHRONIC HBV PATIENTS (updated 11/01/2004)
§
SUSCEPTIBILITY TO ANTIVIRALS OF
AN HBV STRAIN HARBORING POLYMERASE MUTATIONS CONFERRING RESISTANCE TO BOTH
LAMIVUDINE AND ADEFOVIR (updated 11/01/2004)
§
VARIABILITY OF HEPATITIS B
VIRUS SURFACE ANTIGEN IN CHRONIC HEPATITIS B VIRUS CARRIERS WHO PRESENT BOTH
HBS AG AND ANTI-HBS ANTIBODY (updated 11/01/2004)